Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 6/20 | 0.43 |
| ▸ | NPC1 | O15118 | 5/20 | 0.43 |
| ▸ | RAB9A | P51151 | 5/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | MITF | O75030 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | GSK3A | P49840 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | ACP1 | P24666 | 3/20 | 0.39 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.39 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | CCND1 | P24385 | 1/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5899687 | 0.81 | CASP1 (0.51) | CASP1NPC1RAB9ASMN1; SMN2MAOB | |
| SCHEMBL5899743 | 0.81 | CASP1 (0.49) | CASP1MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5899723 | 0.80 | CASP1 (0.50) | CASP1SMN1; SMN2PKMGSK3BLMNA | |
| SCHEMBL6727952 | 0.79 | CASP1 (0.56) | CASP1MAOBGSK3BACP1 | |
| SCHEMBL5899784 | 0.78 | MAOB (0.45) | MAPTNPC1RAB9ASMN1; SMN2MAOB | |
| SCHEMBL5899707 | 0.78 | CASP1 (0.54) | CASP1MAOB | |
| SCHEMBL5899797 | 0.77 | CASP1 (0.55) | CASP1MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5899646 | 0.76 | CASP1 (0.33) | CASP1MAOB | |
| SCHEMBL5899710 | 0.75 | CASP1 (0.54) | CASP1 | |
| SCHEMBL10747907 | 0.74 | CASP1 (0.60) | CASP1MAPTNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110725-A1 | Pyridazines as interleukin-1beta converting enzyme inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2004-06-10 | — | — | US | claimed |
| US-6624166-B1 | Pharmaceutical compositions containing the compounds; and a method for inhibiting interleukin-1 beta protease activity in a mammal utilizing the compounds and compositions for enzyme inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-09-23 | — | — | US | claimed |
| US-6121266-A | TREATMENT/PROPHYLAXIS OF INFLAMMATORY DISEASES, IMMUNE DISEASES, CANCER | VERTEX PHARMACEUTICALS, INC. (US) | 2000-09-19 | — | — | US | claimed |
| EP-0628550-B1 | Pyridazines as interleukin-1beta converting enzyme inhibitors | SANOFI SA (FR) | 1998-02-25 | — | — | EP | claimed |
| EP-0628550-A2 | Pyridazines as interleukin-1beta converting enzyme inhibitors | STERLING WINTHROP INC. (US) | 1994-12-14 | — | — | EP | claimed |
| US-6995261-B2 | 4-pyridazinecarboxamides and esters as interleukin-1β converting enzyme inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-02-07 | — | — | US | disclosed |
| US-20040110725-A1 | Pyridazines as interleukin-1beta converting enzyme inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2004-06-10 | — | — | US | disclosed |
| US-6624166-B1 | Pharmaceutical compositions containing the compounds; and a method for inhibiting interleukin-1 beta protease activity in a mammal utilizing the compounds and compositions for enzyme inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-09-23 | — | — | US | disclosed |
| US-6121266-A | TREATMENT/PROPHYLAXIS OF INFLAMMATORY DISEASES, IMMUNE DISEASES, CANCER | VERTEX PHARMACEUTICALS, INC. (US) | 2000-09-19 | — | — | US | disclosed |
| EP-0628550-B1 | Pyridazines as interleukin-1beta converting enzyme inhibitors | SANOFI SA (FR) | 1998-02-25 | — | — | EP | disclosed |
| EP-0628550-A2 | Pyridazines as interleukin-1beta converting enzyme inhibitors | STERLING WINTHROP INC. (US) | 1994-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110725-A1 | Pyridazines as interleukin-1beta converting enzyme inhibitors | IL6ST, IL1RN, IL1R1 | CASP1 117/4885MAPT 4281/4885NPC1 3007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.